Lipid Formulations in Customized Enteric Capsules Show Promising Results For Oral GLP-1 RA Delivery

Introduction: Oral delivery of GLP-1 receptor agonists would offer a life-changing solution for patients suffering from Type 2 diabetes. However enzymatic degradation and gastrointestinal permeation result in low oral bioavailability of these drug modalities. This study aims to combine Hydrophobic Ion Pairing (HIP), Lipid-Based Formulation (LBF), Permeation Enhancer (PE) with a customized compatible enteric capsule to address above limitations, using Exenatide (EXE) as model GLP-1 RA.